MAZ

Across TCGA pan-cancer cohorts, MAZ Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated MAZ data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MAZ Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAZ expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

OV, BLCA, and HNSC are the cancer types where MAZ Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.059	0.844	<.001	48	view →
BLCA	DFS	Median	All	1.000	0.324	.007	24	view →
HNSC	DFS	Median	III,IV	0.160	0.682	<.001	21	view →
BRCA	DFS	Median	All	0.135	0.528	<.001	20	view →
SKCM	DFS	Median	II,III,IV	0.137	0.685	<.001	15	view →
COAD	OS	Median	All	0.172	0.870	<.001	12	view →
LUAD	OS	Median	III,IV	0.158	0.663	.008	12	view →
LUSC	DFS	Median	All	0.153	0.797	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

MAZ–OV (OS)

Open the OV breakdown →